Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis

Molecular Neurobiology

Volumn 54, Issue 4, 2017, Pages 2961-2968

  Oliveira, Sayonara R ^a   Kallaur, Ana Paula ^a   Reiche, Edna M V ^b   Kaimen Maciel, Damacio R ^a   Panis, Carolina ^c   Lozovoy, Marcell Alysson B ^b   Morimoto, Helena K ^b   Maes, Michael ^d   Dichi, Isaias ^a   Simão, Andrea Name Colado ^b  

^a University Hospital of Londrina   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

^c UNIVERSIDADE ESTADUAL DO OESTE DO PARANÁ   (Brazil)

^d DEAKIN UNIVERSITY   (Australia)

Author keywords

Clinical forms; Inflammation; Multiple sclerosis; Nitrosative stress; Oxidative stress

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; C REACTIVE PROTEIN; CARBONYL DERIVATIVE; FERRITIN; LIPID HYDROPEROXIDE; NITRATE; NITRITE; ALBUMINOID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; SENSITIVITY AND SPECIFICITY; BLOOD; CASE CONTROL STUDY; DIFFERENTIAL DIAGNOSIS; INFLAMMATION; METABOLISM; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NITROSATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOLOGY; STATISTICAL MODEL;

ADULT; ALBUMINS; BIOMARKERS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFLAMMATION; LOGISTIC MODELS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NITROSATION; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 84962215127     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-016-9860-z     Document Type: Article

References (30)

1. LeVine SM, Lynch SG, Ou CN, Wulser MJ, Tam E, Boo N (1999) Ferritin, transferrin and iron concentrations in the cerebrospinal fluid of multiple sclerosis patients. Brain Res 821:511–515
2. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC (2014) Onset of secondary progressive phase and longterm evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry 85:67–75
3. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46:907–911
4. Ferretti G, Bacchetti T, Principi F, Di Ludovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. Mult Scler 11:677–682
5. Oliveira SR, Kallaur AP, Simão AN, Morimoto HK, Lopes J, Panis C, Petenucci DL, da Silva E et al (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321:49–53
6. Haider L (2015) Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Celular Oxid Med Longev 2015:725.370
7. Rossi S, Motta C, Studer V, Barbieri F, Buttari F, Bergami A, Sancesario G, Bernardini S et al (2014) Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 3:304–312
8. Matsushita T, Tateishi T, Isobe N, Yonekawa T, Yamasaki R, Matsuse D, Murai H, Kira J (2013) Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. PLoS One 4, e61835
9. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
10. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69:292–302
11. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444–1452
12. Brazil IBGE (2011) Brazilian Institute of Geography and Statistics. Characteristics of the Population and Households: Results of the Universe. Available in://http://www.ibge.gov.br/english/estatistica/populacao/censo2010/caracteristicas_da_populacao/default_caracteristicas_da_populacao.shtm. Accessed 16 July, 2013.
13. Gonzales-Flecha BG, Llesuy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 10:93–100
14. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, Capeillère-Blandin C, Nguyen AT, Canteloup S, Dayer JM, Jungers P et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–2532
15. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simão AN, Cecchini AL et al (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133:89–97
16. Repetto M, Reides C, Gomez Carretero ML, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 255:107–117
17. Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14:529–533
18. Grune T, Merker K, Sandig G, Davies KJ (2003) Selective degradation of oxidatively modified protein substrates by the proteasome. Biochem Biophys Res Commun 3:709–718
19. Lozovoy MA, Simão AN, Oliveira SR, Iryioda TM, Panis C, Cecchini R, Dichi I (2013) Relationship between iron metabolism, oxidative stress, and insulin resistance in patients with systemic lupus erythematosus. Scand J Rheumatol 4:303–310
20. de Bustos F, Navarro JA, de Andrés C, Molina JA, Jiménez-Jiménez FJ, Ortí-Pareja M, Gasalla T, Tallón-Barranco A et al (1999) Cerebrospinal fluid nitrate levels in patients with multiple sclerosis. Eur Neurol 41:44–47
21. Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L (2003) Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis. J Neuroimmunol 136:112–118
22. Guthikonda P, Baker J, Mattson DH (1998) Interferon-beta-1-b (IFN-β) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol 82:133–139
23. Simão AN, Lozovoy MA, Simão TN, Venturini D, Barbosa DS, Dichi JB, Matsuo T, Cecchini R et al (2011) Immunological and biochemical parameters of patients with metabolic syndrome and the participation of oxidative and nitroactive stress. Braz J Med Biol Res 44:606–728
24. Gonsette RE (2008) Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274:48–53
25. van Meeteren ME, Teunissen CE, Dijkstra CD, van Tol EA (2005) Antioxidants and polyunsaturated fatty acids in multiple sclerosis. Eur J Clin Nutr 59:1347–1361
26. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV (2010) Serum ferritin: past, present and future. Biochim Biophys Acta 1800:760–769
27. Strupp M (2010) News on multiple sclerosis: induction of immune tolerance, a biomarker for predicting disease activity, and CSF ferritin levels. J Neurol 257:2114–2116
28. Connor JR, Boeshore KL, Benkovic SA, Menzies SL (1994) Isoforms of ferritin have a specific cellular distribution in the brain. J Neurosci Res 37:461–465
29. Arosio P, Levi S (2002) Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med 33:457–463
30. Sitar ME, Aydin S, Cakatay U (2013) Human serum albumin and its relation with oxidative stress. Clin Lab 59:945–949